Aerogen Ltd, IDA Business Park, Galway, Ireland.
School of Medicine, UCD Centre for Precision Surgery, University College Dublin, Dublin, Ireland.
Drug Deliv. 2022 Dec;29(1):10-17. doi: 10.1080/10717544.2021.2015482.
Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, ≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.
气溶胶疗法用于将医学治疗药物直接输送到气道以治疗呼吸道疾病。这种治疗形式的一个潜在后果是,无论是源自患者的还是医疗的,都会有逸散性气溶胶释放到环境中,随后照顾者和旁观者会暴露于潜在的病毒感染中。本研究检查了在对模拟成年患者进行标准气溶胶治疗期间这些逸散性气溶胶的释放情况。气溶胶保持室和吸嘴连接到代表性的头部模型和呼吸模拟器上。激光和纹影成像的组合用于非侵入性地可视化逸散性气溶胶颗粒的释放和扩散。使用光学粒子计数器在与模拟患者相关的临床相关位置测量时变气溶胶粒子数浓度和粒径分布。评估了呼吸模式(正常和呼吸困难)、0.2 和 6 LPM 的补充气流以及在吸嘴的呼气口添加细菌过滤器的影响。图像显示大量逸散性气溶胶从未经过滤的吸嘴中释放出来。图像和粒子计数器数据表明,添加细菌过滤器可限制这些逸散性气溶胶的释放,峰值逸散性气溶胶浓度降低了 47.3-83.3%,具体取决于距模拟患者的距离。在吸嘴中添加细菌过滤器可显著降低模拟气溶胶治疗期间逸散性气溶胶的排放水平,≤0.05,这将极大地有助于减少医护人员和旁观者接触潜在有害逸散性气溶胶的风险。